Ultragenyx Pharmaceuticals needed a win for its lead drug burosumab after a midstage pipeline failure and delivered with a good set of phase 3 results. The biotech said the data keep burosumab on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results